AllSci News
Jade Biosciences' anti-BAFF-R antibody entering Phase I for rheumatoid arthritis
Jade Biosciences, a NASDAQ-listed clinical-stage company (ticker: JBIO), has registered a first-in-human Phase I trial of JADE201, an afucosylated,...
Freya Bio's live biotherapeutic shows promise in Phase I trial for IVF embryo implantation failure
Freya Biosciences reported Phase I data for FB301, a defined multi-strain Lactobacillus live biotherapeutic, showing that the vaginally administered product...
Cochrane review of anti-amyloid Alzheimer’s drugs draws researcher pushback over pooled analysis
A Cochrane review published this week suggested that anti-amyloid beta monoclonal antibodies produce “trivial effects” on cognitive function and dementia severity while…
FDA delays review of Savara's molgramostim inhalation solution for autoimmune PAP to November
The US FDA has extended its review period for the Biologics License Application (BLA) submitted by Savara Inc. for molgramostim inhalation solution...
Eli Lilly's orforglipron set for approval filing in diabetes after positive Phase III results
Eli Lilly (NYSE: LLY) reported that orforglipron (Foundayo) met its primary cardiovascular safety endpoint in the Phase III ACHIEVE-4 trial, demonstrating...
National Heart, Lung, and Blood Institute backs LSU Health Sciences Center for microRNA hypertension research
The National Heart, Lung, and Blood Institute has awarded USD 1,008,719 to LSU Health Sciences Center under the R35 Outstanding Investigator Award mechanism...
MeiraGTx reacquires botaretigene sparoparvovec from J&J for USD 25m upfront
MeiraGTx (Nasdaq: MGTX) has acquired all interests in botaretigene sparoparvovec (bota-vec), an AAV-based gene therapy for X-linked retinitis pigmentosa,...
Interna Therapeutics and Daiichi Sankyo partner on molecular nano motor intracellular delivery platform
Interna Therapeutics, a clinical-stage biotechnology company based in Petach Tikva, Israel, announced a research collaboration with Tokyo-listed Daiichi Sankyo (TSE: 4568), conducted…
Partner Therapeutics seeking third indication for Bizengri in NRG1 fusion-positive cholangiocarcinoma
Partner Therapeutics submitted a supplemental Biologics License Application (sBLA) to the US FDA on April 14, 2026 for Bizengri (zenocutuzumab-zbco),...
Bold Therapeutics' Bold-100 shows lower neuropathy rates in Phase I/II FOLFOX combination trial
Bold Therapeutics reported that BOLD-100, its ruthenium-based anticancer agent, was associated with substantially lower rates of oxaliplatin-induced...
AIM ImmunoTech's rintatolimod advances to Phase III trial for pancreatic cancer on positive signals
AIM ImmunoTech (NYSE American: AIM) announced plans to advance rintatolimod (Ampligen) into a Phase III trial for late-stage pancreatic ductal...
University Hospital Erlangen achieves CD19 CAR-T remission in autoimmune hemolytic anemia with ITP
University Hospital Erlangen researchers report CD19 CAR-T-induced remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid...
Immutep secures FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma
Immutep (ASX: IMM; NASDAQ: IMMP) announced receipt of FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma (STS), a rare…
Aligos hands pevifoscorvir license to Xiamen Amoytop in USD 445m deal
Aligos Therapeutics (Nasdaq: ALGS) has entered an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. covering pevifoscorvir sodium, an oral...
RemeGene receives USD 650m upfront fee from AbbVie
RemeGen Co. (HKEX: 9995) confirmed on April 15 that it has received the USD 650 million upfront payment from AbbVie (NYSE: ABBV) under the exclusive license...
The AllSci Brief
Systematic R&D and deal news. Daily.